Droms Strauss Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$242K Sell
264
-4
-1% -$4.05K 0.06% 70
2025
Q4
$288K Buy
+268
New +$256K 0.08% 64

Other funds holding LLY

Droms Strauss Advisors's LLY Position: Q1 2026 in Review

Droms Strauss Advisors reduced its Eli Lilly (LLY) stake by 1.5% in Q1 2026, selling an estimated $4.05K and leaving 264 shares worth $242K. The position accounts for 0.06% of the portfolio, ranked #70.

Droms Strauss Advisors first reported a position in LLY in Q4 2025 and has held it in 2 quarters since. The position peaked at $288K in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Droms Strauss Advisors held 264 shares of Eli Lilly worth $242K as of Q1 2026.
  • Droms Strauss Advisors sold 4 Eli Lilly shares in Q1 2026, an estimated $4.05K.
  • Eli Lilly made up 0.06% of Droms Strauss Advisors's portfolio in Q1 2026, its #70 holding.
  • Droms Strauss Advisors first reported a position in Eli Lilly in Q4 2025 and has held it in 2 quarters since.
  • Droms Strauss Advisors's Eli Lilly position peaked at $288K in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Droms Strauss Advisors's 13F filing for Q1 2026, filed 1 May 2026.